XML 21 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 713 $ 1,203
Restricted cash and restricted cash equivalents 0 604
Accounts and notes receivable, net 770 610
Inventories 1,472 1,352
Prepaid expenses and other 71 66
Total current assets 3,026 3,835
Property, plant, and equipment 9,572 9,412
Less: Accumulated depreciation (6,389) (6,196)
Property, plant, and equipment, net 3,183 3,216
Operating lease right-of-use assets 258 260
Goodwill 46 102
Other intangible assets, net 3 3
Investments in affiliates 152 158
Restricted cash and restricted cash equivalents 50  
Other assets 797 677
Total assets 7,515 8,251
Current liabilities:    
Accounts payable 1,142 1,159
Compensation and other employee-related cost 99 89
Short-term and current maturities of long-term debt 54 51
Current environmental remediation 115 129
Other accrued liabilities 393 1,058
Total current liabilities 1,803 2,486
Long-term debt, net 4,054 3,987
Operating lease liabilities 194 206
Long-term environmental remediation 456 461
Deferred income taxes 35 44
Other liabilities 368 328
Total liabilities 6,910 7,512
Commitments and contingent liabilities
Equity    
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024; 197,519,784 shares issued and 148,587,397 shares outstanding at December 31, 2023) 2 2
Treasury stock, at cost (48,871,602 shares at December 31, 2024; 48,932,387 shares at December 31, 2023) (1,804) (1,806)
Additional paid-in capital 1,055 1,033
Retained earnings 1,718 1,782
Accumulated other comprehensive loss (367) (274)
Total Chemours stockholders’ equity 604 737
Non-controlling interests 1 2
Total equity 605 739
Total liabilities and equity $ 7,515 $ 8,251